Frank Delfino

This inventor holds 28 USPTO granted patents and 13 published patent applications, plus 3 CIPO patents and 8 EPO patents, primarily in Bispecific Antibody Development. Top assignees: Regeneron Pharmaceuticals, Inc., Regeneran Pharmaceuticals, Inc.. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Frank Delfino. Retrieved from https://idiyas.com/inventor/frank-delfino

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 28 (Patent Applications = 13)

% Patents Active = 100.0

CIPO Patents = 3 (Patent Applications = 13)

EPO Patents = 8 (Patent Applications = 20)

Average Co-Inventor Count = 5.7

ph-index = 5

Forward Citations = 116(Granted Patents)

Company Filing History:

25 out of 1,482

Regeneron Pharmaceuticals, Inc.

patents

3 out of 49

Regeneran Pharmaceuticals, Inc.

patents

Years Active: 2016-2026

Loading Chart...

Areas of Expertise:

Chimeric Antigen Receptors

Bispecific Antibodies

Cancer Therapies

HPV Antigen-Binding Proteins

HER2 Binding Molecules

PRLR Antibodies

EGFRvIII Antibodies

Multispecific Antibodies

Anti-STEAP2 Antibodies

FGFR2 Antibodies

Antibody-Drug Conjugates

BCMA x CD3 Antibodies

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12600793 - Chimeric Antigen Receptors with MAGE-A4 Specificity and Uses Thereof (2026-04-14),

2. 12600783 - ANTI-NEW YORK ESOPHAGEAL SQUAMOUS CELL CARCINOMA 1 (NY-ESO-1) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF (2026-04-14),

3. 12583939 - BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND HER2, AND METHODS OF USE THEREOF (2026-03-24),

4. 12297257 - Multispecific antigen-binding molecules and uses thereof (2025-05-13),

5. 12258412 - Nucleic acid molecules encoding bispecific anti-BCMA x anti-CD3 antibodies (2025-03-25),

6. 12150959 - Chimeric antigen receptors with BCMA specificity and uses thereof (2024-11-26),

7. 12115216 - Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof (2024-10-15),

8. 11958910 - Bispecific antigen binding molecules that bind HER2, and methods of use thereof (2024-04-16),

9. 11866502 - Anti-FGFR2 antibodies and methods of use thereof (2024-01-09),

10. 11633501 - Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof (2023-04-25),

11. 11608380 - Anti-EGFRvIII antibodies and uses thereof (2023-03-21),

12. 11559576 - Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof (2023-01-24),

13. 11414494 - Anti-GITR antibodies and uses thereof (2022-08-16),

14. 11384153 - Bispecific anti-BCMA x anti-CD3 antibodies and uses thereof (2022-07-12),

15. 11352446 - Methods of making multispecific antigen-binding molecules (2022-06-07),

Title: **Frank Delfino: Innovations in Cancer Treatment and Beyond**

Introduction

Frank Delfino, a prolific inventor based in Poughquag, NY, has made significant contributions to the field of biomedical innovations with a portfolio of 23 patents. His work largely focuses on addressing critical health challenges, particularly in cancer treatment, through innovative therapeutic methods.

Latest Patents

Among his latest advancements, Delfino's patents include the development of chimeric antigen receptors with specificity for B-cell maturation antigen (BCMA). This invention aims to target malignant plasma cells effectively. The engineered cells derived from this invention exhibit the potential to inhibit tumor growth, particularly in cases of multiple myeloma and other cancers characterized by upregulated BCMA expression. Another notable patent involves the creation of anti-human papillomavirus (HPV) antigen-binding proteins that specifically bind to HLA-displayed HPV peptides, paving the way for therapeutic and diagnostic applications.

Career Highlights

Throughout his career, Frank Delfino has worked with prominent organizations, including Regeneron Pharmaceuticals, Inc. This experience has enabled him to develop several patented technologies that hold promise for enhancing cancer therapies and improving patient outcomes.

Collaborations

Delfino has collaborated with talented individuals such as Jessica Kirshner and Gavin Thurston, contributing to a dynamic and innovative working environment. These collaborations continue to foster advancements in the biomedical sector, highlighting the importance of teamwork in driving innovation.

Conclusion

Frank Delfino's contributions to the field of biomedical innovation, particularly through his patents aimed at treating cancer and HPV-related conditions, exemplify the impactful role of inventors in healthcare advancements. His ongoing work and collaborations signify the potential for future breakthroughs that could transform patient care and treatment methodologies.

Profile summary based on public USPTO records.